Skip to main content
. 2019 Aug 16;20:186. doi: 10.1186/s12931-019-1163-2

Fig. 4.

Fig. 4

Estimated annual reduction in exacerbation rates (see also Tables 2,3,4). In the “overall” model, the estimated decrease is at 6.3% (95% CI (3.9, 8.7)) per calender year. The estimates based on the two disjoint subgroups of placebo controls are very similar, and adjusting for baseline mean SGRQ score or FEV1 also leads to consistent effects